Mirae Asset ELSS Tax Saver Fund
The scheme seeks to generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related instruments.
Growthvine rating: 4/5 — ranked #6 of 57 in category.
Fund basics
| Category | Equity: ELSS |
|---|
| NAV | ₹46.76 (as of 2026-10-22) |
|---|
| AUM | ₹26,428 Cr |
|---|
| Expense ratio | 1.38% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Neelesh Surana |
|---|
| Exit load | 0 |
|---|
Performance & risk
| 5-year annualised return | 8.77% |
|---|
| Sharpe ratio | 0.32 |
|---|
| Standard deviation | 16.01% |
|---|
| Max drawdown | −37.97% |
|---|
| Alpha | 0.74 |
|---|
| Beta | 1.01 |
|---|
Over 5 years, captured 96.5% of Nifty 500's upside and 96.3% of its downside.
Market cap allocation
| Large cap | 58.3% |
|---|
| Mid cap | 21.1% |
|---|
| Small cap | 20.6% |
|---|
Concentration
| Top 5 holdings | 26.9% |
|---|
| Top 10 holdings | 41.4% |
|---|
| Total holdings | 68 |
|---|
| Index overlap | 40.4% |
|---|
| Active share | 59.6% |
|---|
Top holdings
- HDFC Bank Ltd. — 8.8%
- ICICI Bank Ltd. — 5.2%
- Laurus Labs Limited — 4.6%
- Reliance Industries Ltd — 4.3%
- State Bank Of India — 4.1%
- AXIS Bank Ltd. — 3.7%
- Bharti Airtel Ltd. — 3.6%
- Delhivery Limited — 2.4%
- Hindalco Industries Ltd. — 2.4%
- Sun Pharmaceutical Industries Ltd. — 2.3%
Top sectors
- Banking & Financial — 26.4%
- Pharma & Biotech — 8.9%
- Automobile — 8.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −8.6% | Q3 | #35 of 52 |
| 2025 | 9.7% | Q1 (Top) | #6 of 51 |
| 2024 | 17.2% | Q3 | #31 of 51 |
| 2023 | 27.0% | Q3 | #28 of 48 |
| 2022 | 0.1% | Q3 | #32 of 43 |